Text Size

European Cardiac Resynchronisation Therapy Survey

This study has been completed.
Sponsor:
Collaborators:
Boston Scientific Corporation
Medtronic
St. Jude Medical
Biotronik SE & Co. KG
Sorin Group
Roche Diagnostic Ltd.
Information provided by (Responsible Party):
Nigussie Bogale, Helse Stavanger HF
ClinicalTrials.gov Identifier:
NCT01185392
First received: August 7, 2010
Last updated: June 7, 2012
Last verified: June 2012
History of Changes

August 7, 2010
June 7, 2012
November 2008
June 2009   (final data collection date for primary outcome measure)
To describe current European CRT implantation practice and there is a need to precisely quantify the extent of treatment failures, adverse experience and complications associated with implantation. [ Time Frame: November 2008-October 2010 ] [ Designated as safety issue: No ]

The Survey will capture data from patients receiving CRT-P/CRT-D devises:

  • Demographics and clinical characteristics
  • Diagnostic criteria assessed prior to implantation
  • Pharmacological therapy at baseline and follow-up
  • Implantation procedure and techniques
  • Device programming
  • Short and long-term outcomes
  • Adverse experience and hospitalisation
  • Economic analyses
  • Adherence to guidelines

These data should also provide information contrasting practice between centres and countries and adherence to guideline recommendations.
Same as current
Complete list of historical versions of study NCT01185392 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
European Cardiac Resynchronisation Therapy Survey
European Cardiac Resynchronisation Therapy Survey

The European CRT survey represents a joint initiative between two ESC associations; the Heart Failure Association and the European Heart Rhythm Association. The survey will be performed in collaboration with The Institute für Herzinfarktforschung in Ludwigshafen which will handle the data collection and data analysis.

This European CRT Survey was initiated by the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the ESC in order to describe current European practice and routines associated with CRT-P/CRT-D implantations based on sample of patients enrolled in 13 countries. The data collected following implantation provides information including clinical characteristics, diagnostic criteria, implantation routines and techniques, adverse experience, and assessment of adherence to guideline recommendations. The single follow-up visit at 1 year (9-15 months) will provide information regarding short-term clinical outcomes.

The primary objective of this Survey is to describe current European practice based on a broad sampling in 13 countries. The information collected will enable practice between centres and countries to be compared and permit benchmarking with national and international practice. The survey provides valuable quality assurance assessment for individual centres, permits limited economic analyses and broadly evaluates adherence to guideline recommendations.

The following 13 European countries contributed patients to the survey: Austria, Belgium, France, Germany, Ireland, Israel, Italy, the Netherlands, Norway, Spain, Sweden, Switzerland and UK. Two national coordinators, one each from the fields of heart failure and electrophysiology, were selected and given the responsibility to facilitate recruitment in their respective countries.

Follow the link for complete list of the members of the Scientific Committee and national coordinators.
Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

All consecutive patients successfully implanted with a new CRT-P, CRT-D or upgrades during the inclusion period were eligible. The successful procedure itself identified the patient as a survey candidate. Patients screened but not successfully implanted were not entered into the survey. Ethics approval and written informed consent were obtained in countries where required.
Heart Failure
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2438
January 2012
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • eligible patients for CRT-P or CRT-D.

Exclusion Criteria:

  • none
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01185392
CRT Survey
No
Nigussie Bogale, Helse Stavanger HF
Helse Stavanger HF
  • Boston Scientific Corporation
  • Medtronic
  • St. Jude Medical
  • Biotronik SE & Co. KG
  • Sorin Group
  • Roche Diagnostic Ltd.
Study Chair: Kenneth Dickstein, MD, PHD HFA of the ESC
Study Chair: Silvia Priori, MD, PHD EHRA of the ESC
Study Director: Angelo Auricchio, MD, PHD EHRA of the ESC
Study Director: Josep Brugada, MD, PHD EHRA of the ESC
Study Director: John Cleland, MD, PHD HFA of the ESC
Study Director: Geneviève Derumeaux, MD, PHD EAE of the ESC
Study Director: Daniel Gras, MD, PHD EHRA of the ESC
Study Director: Michel Komajda, MD, PHD HFA of the ESC
Study Director: Cecilia Linde, MD, PHD EHRA of the ESC
Study Director: John Morgan, MD, PHD EHRA of the ESC
Study Director: Dirk J van Veldhuisen, MD, PHD HFA of the ESC
Study Director: Anselm Gitt, MD The Institut für Herzinfarktforschung in Ludwigshafen, Germany
Study Director: Nigussie Bogale, MD Stavanger University Hospital and University of Bergen, Norway
Helse Stavanger HF
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP